Nephros Inc. (NASDAQ:NEPH) Short Interest Update

by · The Cerbat Gem

Nephros Inc. (NASDAQ:NEPH – Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 8,451 shares, an increase of 133.1% from the December 15th total of 3,625 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 40,853 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 40,853 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.

Nephros Stock Performance

NEPH stock traded down $0.03 during trading on Thursday, reaching $4.38. The company had a trading volume of 49,667 shares, compared to its average volume of 56,317. The company has a market cap of $46.55 million, a price-to-earnings ratio of 33.69 and a beta of 1.41. Nephros has a twelve month low of $1.39 and a twelve month high of $6.42. The firm has a 50-day simple moving average of $4.98 and a 200-day simple moving average of $4.54.

Nephros (NASDAQ:NEPH – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. Nephros had a net margin of 8.26% and a return on equity of 15.81%. The business had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $3.87 million.

Analyst Ratings Changes

NEPH has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research report on Wednesday, October 8th. Wall Street Zen raised Nephros to a “strong-buy” rating in a research report on Saturday, October 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Read Our Latest Stock Report on Nephros

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Citadel Advisors LLC raised its stake in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after purchasing an additional 4,655 shares during the last quarter. Topline Capital Management LLC increased its holdings in Nephros by 24.9% in the 3rd quarter. Topline Capital Management LLC now owns 596,300 shares of the company’s stock worth $2,820,000 after buying an additional 118,851 shares during the period. Dimensional Fund Advisors LP purchased a new position in Nephros during the 3rd quarter worth approximately $64,000. Finally, Geode Capital Management LLC raised its position in Nephros by 3.2% during the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after buying an additional 2,898 shares during the last quarter. 41.10% of the stock is owned by institutional investors and hedge funds.

Nephros Company Profile

(Get Free Report)

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.

Read More